GH Research PLC (GHRS): Price and Financial Metrics
GHRS Price/Volume Stats
Current price | $10.95 | 52-week high | $14.99 |
Prev. close | $9.61 | 52-week low | $5.05 |
Day low | $9.50 | Volume | 95,000 |
Day high | $11.09 | Avg. volume | 79,758 |
50-day MA | $7.87 | Dividend yield | N/A |
200-day MA | $10.16 | Market Cap | 569.71M |
GHRS Stock Price Chart Interactive Chart >
GH Research PLC (GHRS) Company Bio
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
GHRS Price Returns
1-mo | 31.93% |
3-mo | -4.62% |
6-mo | -20.07% |
1-year | 58.47% |
3-year | -55.58% |
5-year | N/A |
YTD | 88.79% |
2023 | -40.33% |
2022 | -58.34% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...